Pharmaceutical agent containing Rho kinase inhibitor
A Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly as a therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic agent of immature birth, a therapeutic agent of arteriosclerosis, an anti-cancer drug, an anti-inflammatory agent, an immunosuppressant, a therapeutic agent of autoimmune disease, an anti-AIDS drug, a contraceptive, a prophylactic agent of digestive tract infection, a therapeutic agent of osteoporosis, a therapeutic agent of retinopathy and a brain function improving drug. In addition, the Rho kinase inhibitor is provided as a reagent and a diagnostic.
1. A method for treatment of cancer, immune disease, autoimmune disease, AIDS, osteoporosis, immature birth, or fertilization and nidation of fertilized egg, comprising administering a pharmaceutically effective amount of a Rho kinase inhibitor to a patient in need thereof, wherein the Rho kinase inhibitor comprises a substituted isoquinolinesulfonamide compound comprising of the formula (II):
wherein R 12 represents a hydrogen atom, a chlorine atom or a hydroxyl group; and
when R 12 represents a hydrogen atom,
Alk represents an ethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, a phenyl group or a benzyl group,
R 13 and R 14 are directly bonded with each other, thereby forming a trimethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, a phenyl group or a benzyl group, and
R 15 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and
when R 12 represents a chlorine atom or a hydroxyl group,
Alk represents an alkylene group having 2 to 6 carbon atoms, said group being unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms,
R 13 and R 14 are not bonded with each other and each independently represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, or R 13 and R 14 are directly bonded with each other, thereby forming an ethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms or a trimethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, and
R 15 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an amidino group,
an isomer thereof and/or a pharmaceutically acceptable acid addition salt thereof.
2. The method according to claim 1 , wherein the administration is for treatment of cancer.
3. The method according to claim 1 , wherein the administration is for treatment of an immune disease.
4. The method according to claim 1 , wherein the administration is for treatment of an autoimmune disease.
5. The method according to claim 1 , wherein the administration is for treatment of AIDS.
6. The method according to claim 1 , wherein the administration is for treatment of osteoporosis.
7. The method according to claim 1 , wherein the administration is for treatment of immature birth.
8. The method according to claim 1 , wherein the administration is for treatment of fertilization and nidation of fertilized egg.
9. A method for inhibiting Rho kinase activity in a sample, which comprises contacting the sample with an effective amount of a Rho kinase inhibitor comprising a substituted isoquinolinesulfonamide compound of the formula (II):
wherein R 12 represents a hydrogen atom, a chlorine atom or a hydroxyl group; and
when R 12 represents a hydrogen atom,
Alk represents an ethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, a phenyl group or a benzyl group,
R 13 and R 14 are directly bonded with each other, thereby forming a trimethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, a phenyl group or a benzyl group, and
R 15 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and
when R 12 represents a chlorine atom or a hydroxyl group,
Alk represents an alkylene group having 2 to 6 carbon atoms, said group being unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms,
R 13 and R 14 are not bonded with each other and each independently represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, or R 13 and R 14 are directly bonded with each other, thereby forming an ethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms or a trimethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, and
R 15 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an amidino group,
an isomer thereof and/or a pharmaceutically acceptable acid addition salt thereof,
wherein said sample is obtained from a patient having cancer, immune disease, autoimmune disease, AIDS, osteoporosis, immature birth, or fertilization and nidation of fertilized egg.
10. A method for diagnosing a disease caused by Rho kinase, which comprises contacting a sample with a Rho kinase inhibitor comprising a substituted isoquinolinesulfonamide compound of the formula (II):
wherein R 12 represents a hydrogen atom, a chlorine atom or a hydroxyl group; and
when R 12 represents a hydrogen atom,
Alk represents an ethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, a phenyl group or a benzyl group,
R 13 and R 14 are directly bonded with each other, thereby forming a trimethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, a phenyl group or a benzyl group, and
R 15 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and
when R 12 represents a chlorine atom or a hydroxyl group,
Alk represents an alkylene group having 2 to 6 carbon atoms, said group being unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms,
R 13 and R 14 are not bonded with each other and each independently represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, or R 13 and R 14 are directly bonded with each other, thereby forming an ethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms or a trimethylene group unsubstituted or substituted with an alkyl group having 1 to 6 carbon atoms, and
R 15 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an amidino group,
an isomer thereof and/or a pharmaceutically acceptable acid addition salt thereof,
wherein said disease is cancer, immune disease, autoimmune disease, AIDS, osteoporosis, immature birth, or fertilization and nidation of fertilized egg.